Related references
Note: Only part of the references are listed.SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective
Abdo A. Elfiky
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2021)
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study
Thomas Marjot et al.
JOURNAL OF HEPATOLOGY (2021)
Tanta Protocol for Management of COVID-19: Perspectives from a Devel- oping Country
Sherief Abd-Elsalam et al.
ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS (2021)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings
Pascale M. Abena et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know
Jinoos Yazdany et al.
ANNALS OF INTERNAL MEDICINE (2020)
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19 A Living Systematic Review
Adrian V. Hernandez et al.
ANNALS OF INTERNAL MEDICINE (2020)
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
Du Yin-Xiao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19
Kei Irie et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV
Mingxuan Xie et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
Shiv Kumar Sarin et al.
HEPATOLOGY INTERNATIONAL (2020)
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery
Wei Zhu et al.
SLAS DISCOVERY (2020)
Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials
Morteza Arab-Zozani et al.
BMJ OPEN (2020)
SARS-CoV-2: The Path of Prevention and Control
Amal A. Mohamed et al.
Infectious Disorders - Drug Targets (2020)
Chloroquine as Chemoprophylaxis for COVID-19: Will This Work
Sherief Abd-Elsalam et al.
Infectious Disorders - Drug Targets (2020)
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
Kent Doi et al.
CRITICAL CARE (2020)
MERS, SARS and other coronaviruses as causes of pneumonia
Yudong Yin et al.
RESPIROLOGY (2018)
The mechanism of resistance to favipiravir in influenza
Daniel H. Goldhill et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Ebola virus dynamics in mice treated with favipiravir
Vincent Madelain et al.
ANTIVIRAL RESEARCH (2015)
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
Lisa Oestereich et al.
ANTIVIRAL RESEARCH (2014)
G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences
Franz Faul et al.
BEHAVIOR RESEARCH METHODS (2007)
Mechanism of action of T-705 against influenza virus
Y Furuta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Share Paper
